Want to see ARTL full AI Analyst Report?
Top Page
Artelo Biosciences
(NASDAQ:ARTL)
Select Model
Select Model
Rating:40Underperform
Price Target:
$2.00
▲(177.78% Upside)
Action:Downgraded
Date:10/27/26
The score is driven primarily by weak financial performance (no revenue, sizable losses, and worsening cash burn), reinforced by bearish technicals (price well below all key moving averages with negative MACD and very weak momentum). Valuation provides limited support given the negative P/E and lack of dividend data.
Positive Factors
Low Leverage
Very low debt limits interest obligations and reduces balance-sheet pressure while the company funds clinical development. This provides more flexibility than a highly leveraged structure, although operating losses still require careful capital planning and external funding.
Negative Factors
Pre-Revenue Operating Model
Artelo has not yet demonstrated commercial revenue to offset research and development costs, leaving its earnings profile dependent on future clinical and regulatory progress. Persistent operating losses reduce financial resilience and limit visibility into a path toward self-funded growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Very low debt limits interest obligations and reduces balance-sheet pressure while the company funds clinical development. This provides more flexibility than a highly leveraged structure, although operating losses still require careful capital planning and external funding.
Read all positive factors
Artelo Biosciences (ARTL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.21M
Dividend YieldN/A
Average Volume (3M)949.12K
Price to Earnings (P/E)―
Beta (1Y)-0.70
Revenue GrowthN/A
EPS Growth59.79%
CountryUS
Employees7
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-74.28
Shares Outstanding547,774
10 Day Avg. Volume37,028
30 Day Avg. Volume949,117
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-2.26
Price to Sales (P/S)0.00
P/FCF Ratio-0.34
Enterprise Value/Market Cap-0.92
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.09
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-88.56
Revenue Forecast (FY)N/A
Artelo Biosciences Business Overview & Revenue Model
Company Description
Artelo Biosciences, Inc. functions as a clinical-stage biopharmaceutical enterprise dedicated to discovering and advancing therapies that modulate the endocannabinoid system. The company's robust developmental portfolio encompasses several promisi...
Artelo Biosciences Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
15
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Aug 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -12.05M | -12.54M | -9.83M | -9.29M | -10.08M | -7.44M |
| Net Income | -12.67M | -12.88M | -9.83M | -9.29M | -10.08M | -7.44M |
Balance Sheet | ||||||
| Total Assets | 6.46M | 2.80M | 4.70M | 13.04M | 20.42M | 12.63M |
| Cash, Cash Equivalents and Short-Term Investments | 4.20M | 600.00K | 2.34M | 10.43M | 17.53M | 10.06M |
| Total Debt | 49.00K | 678.00K | 104.00K | 23.00K | 63.00K | 95.00K |
| Total Liabilities | 1.46M | 4.07M | 1.84M | 1.29M | 1.02M | 593.00K |
| Stockholders Equity | 5.00M | -1.27M | 2.86M | 11.75M | 19.40M | 12.04M |
Cash Flow | ||||||
| Free Cash Flow | -12.63M | -8.52M | -8.35M | -8.21M | -8.01M | -6.14M |
| Operating Cash Flow | -12.63M | -8.52M | -8.35M | -8.21M | -8.01M | -6.14M |
| Investing Cash Flow | -62.00K | -62.00K | 7.77M | 3.51M | 2.96M | -3.44M |
| Financing Cash Flow | 14.85M | 6.87M | 112.00K | 567.00K | 0.00 | 14.11M |
Artelo Biosciences Technical Analysis
Negative
0.72
Price Trends
4.54
Negative
6.95
Negative
22.35
Negative
Market Momentum
-0.67
Negative
26.74
Positive
11.56
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARTL, the sentiment is Negative. The current price of 0.72 is below the 20-day moving average (MA) of 3.02, below the 50-day MA of 4.54, and below the 200-day MA of 22.35, indicating a bearish trend. The MACD of -0.67 indicates Negative momentum. The RSI at 26.74 is Positive, neither overbought nor oversold. The STOCH value of 11.56 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ARTL.
Artelo Biosciences Risk Analysis
Artelo Biosciences disclosed 56 risk factors in its most recent earnings report. Artelo Biosciences reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Artelo Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $507.59M | -0.47 | -302.75% | ― | ― | 81.43% | |
47 Neutral | $8.63M | -0.28 | -93.49% | ― | ― | 94.38% | |
44 Neutral | $6.36M | -0.09 | -168.05% | ― | ― | 87.05% | |
43 Neutral | $505.53K | -0.06 | -42.42% | ― | ― | 97.97% | |
40 Underperform | $1.21M | -0.03 | -519.09% | ― | ― | 59.79% |
* Healthcare Sector Average
ARTL
Artelo Biosciences
2.33
-92.98
-97.56%
BDRX
Biodexa Pharmaceuticals
4.14
-233.46
-98.26%
TOVX
Theriva Biologics
0.19
-0.12
-39.03%
INDP
Indaptus Therapeutics
3.33
>-0.01
-0.30%
ENVB
Enveric Biosciences
1.47
-5.23
-78.06%
Artelo Biosciences Corporate Events
Business Operations and StrategyDelistings and Listing ChangesRegulatory Filings and Compliance
Artelo Biosciences Addresses Nasdaq Listing Compliance Uncertainty
Negative
Oct 9, 2026
On July 22, 2026, the SEC approved Nasdaq’s new $5,000,000 market value of listed securities rule, which exposes companies below that threshold, including Artelo Biosciences, to potential delisting unless they regain compliance. The rule was...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.